OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

WARSAW, Poland, Jan. 14, 2022 /PRNewswire/ — OncoArendi Therapeutics S.A. (“OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and develop first in class small molecule drug candidates that directly modulate RNA…